富臨精工(300432.SZ):擬投資建設機器人智能電關節模組研發及生產基地項目
格隆匯2月12日丨富臨精工(300432.SZ)公佈,爲滿足富臨精工股份有限公司機器人產業發展需要,加快機器人關鍵硬件智能電關節的開發與產業化,公司與綿陽市涪城區人民政府友好協商,擬簽訂《機器人智能電關節模組研發及生產基地項目投資協議》,公司擬在綿陽市涪城區投資建設機器人智能電關節模組研發及生產基地項目,項目總投資金額11,000萬元。項目建設內容:建成1條機器人智能電關節模組生產線,產品主要應用於人形機器人、機器狗等領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.